Double recognition for SciBite in Bio-IT World Innovative Practices Awards 2023
Cambridge, UK | April 28, 2023
Award-winning solutions to de-silo data advance precision medicine and pharmaceutical R&D projects
SciBite, an Elsevier company and leading provider of semantic software solutions for the life sciences industry, has won an Innovative Practices Award at Bio-IT World 2023 for its collaboration with the City of Hope, a world-renowned cancer research and treatment center, on the Precision Oncology Software Environment Interoperable Data Ontologies Network (POSEIDON) project. The SciBite platform was also recognized for its pivotal role as the ontology ecosystem in AbbVie’s Innovative Practices Award win for their R&D Convergence Hub (ARCH) project, which is driving convergence in AbbVie R&D as a centralized knowledge platform.
POSEIDON project with City of Hope
City of Hope's vision for POSEIDON was to create a highly scalable, compliant, cloud-based platform to unlock the wealth of data captured in their precision medicine program. POSEIDON aims to de-silo legacy and current clinical data, foster collaboration, and make complex clinical and multi-omic data accessible to investigators across City of Hope's network of more than 35 hospitals and treatment centers.
The key challenges that POSEIDON aims to address are the de-siloing of primary and secondary clinical research data and harmonizing this data to facilitate findability and accessibility. POSEIDON enables investigators to access and visualize clinical and multi-omics data. It provides an engine that can be utilized for cohort discovery and exploration, preliminary feasibility testing, deriving patient-specific insights based on real-world data and evidence, and delivering real-world insights.
To create this harmonized data, POSEIDON employs both CENtree and TERMite, SciBite’s ontology management platform and named entity recognition engine, respectively. Administrators use CENtree to maintain a single source of truth between data standards (including various data domains, like medications).
"We are honored to receive this award from Bio-IT World. The collaboration between City of Hope and SciBite demonstrates the importance of a data-centric approach to reach the full potential of scientific data assets. We are proud that SciBite’s technology and domain expertise on this project will enhance City of Hope’s precision medicine platform (POSEIDON) capabilities and ultimately contribute toward better treatment for patients,” said Julien Debeauvais, Vice President, Sales and Alliances, at SciBite.
ARCH project with AbbVie
The AbbVie R&D Convergence Hub, also known as the ARCH, sought to break down silos and improve the R&D process by developing a technology platform that offered operational, analytical, and experiential value for AbbVie’s R&D community.
The ARCH platform leverages tools from SciBite and Modak to bring together vast and diverse data from internal and external platforms and warehouses. SciBite’s CENtree platform, in particular, was instrumental in democratizing the creation and management of ontologies, which were essential to developing and deploying pipelines that could harmonize disparate data sets.
The Innovative Practice Award highlights the highest levels of collaboration and creativity in the life sciences industry as demonstrated in this project.
“We are thrilled to be recognized as part of this prestigious award, which is a testament to our team's hard work and dedication,” said Neal Dunkinson, Vice President Solutions & Professional Services at SciBite. “AbbVie’s use of SciBite’s technology is an excellent example of how our ontology management platform can help organizations break down silos and improve data integration and analysis.
These awards build on last year’s Bio-IT World success, SciBite’s Best in Show win for CENtree. The awards ceremony will be held during the opening plenary program on Tuesday, May 16, at the 2023 Bio-IT World Conference & Expo in Boston.
---
Notes for editors
About Bio-IT World
The Bio-IT World Conference & Expo is the world’s premier event showcasing the technologies and analytic approaches that solve problems, accelerate science, and drive the future of precision medicine. The event unites a community of leading life sciences, pharmaceutical, clinical, healthcare, informatics, and technology experts in biomedical research, drug discovery and development, and healthcare worldwide.
About City of Hope
City of Hope's mission is to deliver the cures of tomorrow to the people who need them today. Founded in 1913, City of Hope has grown into one of the largest cancer research and treatment organizations in the U.S. and one of the leading research centers for diabetes and other life-threatening illnesses. City of Hope research has been the basis for numerous breakthrough cancer medicines and human synthetic insulin and monoclonal antibodies.
With an independent, National Cancer Institute-designated comprehensive cancer center at its core, City of Hope brings a uniquely integrated model to patients spanning cancer care, research and development, academics and training, and innovation initiatives. City of Hope’s growing national system includes its Los Angeles campus, a network of clinical care locations across Southern California, a new cancer center in Orange County, California, and treatment facilities in Atlanta, Chicago and Phoenix. City of Hope’s affiliated group of organizations includes Translational Genomics Research Institute and AccessHope™. Find out more at www.cityofhope.org opens in new tab/window.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. They strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology, in addition to products and services across the Allergan Aesthetics portfolio. For more information about AbbVie, please visit www.abbvie.com opens in new tab/window.
About SciBite
SciBite’s data-first, semantic analytics software is for those who want to innovate and get more from their data. Leading the way by pioneering the combination of the latest in machine learning with an ontology-led approach, SciBite’s semantic infrastructure answers business-critical questions in real-time by releasing the value and full potential of unstructured data.
Supporting the world’s leading scientific organizations with use cases from discovery through to development, SciBite’s suite of fast, flexible, deployable API technologies empowers customers, making it a critical component in scientific, data-led strategies. Find out more at https://scibite.com opens in new tab/window.
About Elsevier
As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.
We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.
Together with the Elsevier Foundation opens in new tab/window, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.
Elsevier is part of RELX opens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.